Loading…
← CockpitCompetitor Analysis › RARE Ultragenyx Pharmaceutical, Inc.Open in the cockpit ↗

Ultragenyx Pharmaceutical, Inc.RARECompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Rare-disease biopharma with several approved drugs (Crysvita, Dojolvi, Mepsevii) and a broad gene-therapy pipeline.

Momentum weak 29
Mkt cap
$1.81B
US dollars, full cap
Free float
91%
of shares outstanding
$/day
$63.4M
20-day average traded
Fwd P/E
9.6×
forward earnings
ROIC−WACC
-73.6 pp
WACC 6.4%
Hurdle
n/a
no reverse DCF
Next earnings
92 days
18 Feb 2027
Close · USD$17.73
1D+6.2%
1W+6.2%
1M+10.7%
3M-30.0%
6M-24.1%
YTD-22.9%
1Y-45.5%
ATR %5.0%
Beta1.38
52w lowhigh55.5% off high

What Ultragenyx Pharmaceutical does

Rare-disease biopharma with several approved drugs (Crysvita, Dojolvi, Mepsevii) and a broad gene-therapy pipeline.

Each medicine serves very few patients and is sold at a high price per patient, so a handful of products carry the company. Crysvita, the largest, is shared with Kyowa Kirin. Gene therapies under development are funded by that income and by share sales.

Products and services

  • Crysvita (XLH, with Kyowa Kirin)
  • Dojolvi (LC-FAOD)
  • Mepsevii (MPS VII)
  • Gene-therapy pipeline (Sanfilippo, etc.)

Customers

  • Rare-disease specialists
  • Pediatric metabolic clinics

Where it sits in the supply chain

  • Rare-disease biopharma
  • Enzyme-replacement & gene-therapy…
  • Multi-product rare-disease…

What could go right

  • Crysvita royalty/revenue growth
  • Gene-therapy pipeline approvals

What could go wrong

  • High R&D spend across many small-market programs
  • Ultra-rare-disease commercial scale limits

Moat: narrow (IP / patents, regulatory licence). Multiple orphan-drug approvals in ultra-rare diseases with few or no competitors.

Headquarters: Novato, California, US · Founded: 2010 · Employees: 1,371

Named competitors

Ultragenyx Pharmaceutical at a glance

Size Ultragenyx Pharmaceutical (RARE) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.81B, the 1845th largest of 3,085 United States companies the cockpit tracks. Shares closed at $17.73 on 18 Nov 2026.

Performance Over six months the shares fell 24.1%, against -7.3% for the median peer and -2.2% for the United States market (cap-weighted) — 6th lowest of 21 in its peer set.

Growth Revenue grew 15.8% over the last twelve months (peer median +4.2%); the operating margin is -64.1% (peer median 10.0%).

Valuation It trades at 9.6× forward earnings against a peer median of 19.7× (cheapest of 18).

Capital Return on invested capital runs 73.6 points below its cost of capital (6.4% WACC).

Short interest Short interest is 23.2% of the free float (30 Oct 2026).

Next results Next results expected around 18 Feb 2027 (exchange calendar; dates can move).

Relative performance

5010015021 May 202621 Aug 202618 Nov 2026Peer median 95RARE 75
Six months, rebased to 100: Ultragenyx Pharmaceutical against the median of its 20 peers (local-currency closes).

Ultragenyx Pharmaceutical financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$730M$673M$560M$434M$363M
Revenue growth—+20%+29%+20%—
Gross profit$571M$537M$453M$367M$320M
EBITDA-$434M-$500M-$500M-$543M-$631M
Net income-$524M-$575M-$569M-$607M-$707M
Free cash flow-$442M-$472M-$422M-$519M-$497M
Capital expenditure$9.94M$21.0M$20.0M$46.8M$146M
Total debt$1.19B$1.25B$910M$935M$907M

Quarterly statements and history in the cockpit →

Ultragenyx Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%-20%-10%0%+10%301015002399ZYME0000283933605507ETON300573600664AGIODMP000908COHANCE600211300009PFIZERNATCOPHARMALIVUS688166MAZERARE6-month return →1-month return →
Up and to the right = strong over both horizons. Ultragenyx Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×50×100×150×301015002399ZYME000028ETON300573600664COHANCEPFIZERNATCOPHARM688166RARERevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Ultragenyx Pharmaceutical is the large dot.

Ultragenyx Pharmaceutical competitors and peer comparison

Head to head with its named competitors (RARE vs BMRN vs SAN.PA vs IONS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Ultragenyx Pharmaceutical RARE$1.81B-24%+16%-64%9.6×n/a
BioMarin Pharmaceutical BMRN$11.9B+22%+20%19%11.2×8.2%
Sanofi SAN.PA$114B+13%+15%27%9.7×-4.8%
Ionis Pharmaceuticals IONS$4.56B-64%-1%-59%n/an/a

How Ultragenyx Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Ultragenyx Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
MeasureRAREPeer medianRank in peer set
1-month return+10.7%-1.0%3rd highest of 21
6-month return-24.1%-7.3%6th lowest of 21
Distance from 52-week high-55.5%-32.8%2nd lowest of 21
Revenue growth (TTM)+15.8%+4.2%5th highest of 21
Operating margin-64.1%10.0%3rd lowest of 21
Forward P/E9.6×19.7×cheapest of 18
ROIC minus cost of capital-73.6 pp+2.4 pp3rd lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Ultragenyx Pharmaceutical RAREUnited States$1.81B-24%+16%-64%9.6×n/an/a
Qingdao Baheal Medical 301015.SZChina$1.81B+2%-6%8%21.0×10.1%+5.0%
Shenzhen Hepalink Pharmaceutical 002399.SZChina$1.80B-12%-6%8%25.8×-0.7%+0.5%
Zymeworks ZYMEUnited States$1.81B+5%+98%17%160.4×n/an/a
China National Accord Medicines 000028.SZChina$1.81B-3%0%2%10.8×-9.5%+4.2%
United Laboratories International 3933.HKHong Kong$1.80B-20%-13%5%13.0×1.2%+7.8%
Guobang Pharma 605507.SSChina$1.82B-6%+3%12%15.7×-6.0%+7.4%
Eton Pharmaceuticals ETONUnited States$1.79B+226%+101%29%24.6×21.9%+359.6%
Shenyang Xingqi Pharmaceutical 300573.SZChina$1.83B-25%+17%33%13.0×5.4%+29.1%
Harbin Pharmaceutical 600664.SSChina$1.78B+32%+2%5%19.7×-5.3%+8.2%
Agios Pharmaceuticals AGIOUnited States$1.78B+4%+214%-298%n/an/an/a
Dermapharm DMP.DEGermany$1.85B-29%+2%21%13.2×-3.4%+8.0%
CSPC Hunan Jingfeng Pharmaceutical 000908.SZChina$1.85B-38%+5%-18%n/an/an/a
Cohance Lifesciences COHANCE.NSIndia$1.87B+7%+14%2%96.3×n/an/a
Tibet Rhodiola Pharmaceutical 600211.SSChina$1.87B-8%+13%27%12.5×-1.2%+16.7%
Anhui Anke Biotechnology (Group) 300009.SZChina$1.88B-12%-9%30%18.1×8.0%+9.3%
Pfizer PFIZER.NSIndia$1.88B-20%+12%34%21.9×11.2%+2.4%
NATCO Pharma NATCOPHARM.NSIndia$1.73B-27%-30%17%19.1×20.5%+19.0%
Alivus Life Sciences ALIVUS.NSIndia$1.90B+36%+8%31%23.8×20.1%+6.2%
BrightGene Bio-Medical Technology 688166.SSChina$1.71B-57%+14%7%74.9×35.3%+9.2%
Maze Therapeutics MAZEUnited States$1.71B+27%-100%-821%n/an/an/a

Questions

Who are Ultragenyx Pharmaceutical's main competitors?
Named competitors: BioMarin Pharmaceutical (BMRN), Sanofi (Genzyme) (SAN.PA), Ionis Pharmaceuticals (IONS). The cockpit's measured peer set (industry) also includes Qingdao Baheal Medical (301015.SZ), Shenzhen Hepalink Pharmaceutical (002399.SZ), Zymeworks (ZYME), China National Accord Medicines (000028.SZ), United Laboratories International (3933.HK), Guobang Pharma (605507.SS).
Is Ultragenyx Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 9.6× against a peer median of 19.7×, cheapest of 18 in its peer set.
How has Ultragenyx Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -24.1% against -7.3% for the median peer; over one year -45.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.